Sharing-our-perspective-page-header2



Sharing perspectives leads to greater understanding and fuels innovation. The ​Optum Insights ​blog is where we share our perspective and challenge preconceptions to clear a new path forward



  • FDA approves new opioid analgesic - Dsuvia™ (sufentanil sublingual tablet)

    by
    • Optum Workers' Comp
    | Nov 06, 2018
    Tag Icon
    Pain Management, Opioids, FDA, Clinical
    On November 2, 2018, the U.S. Food and Drug Administration (FDA) approved the first and only sufentanil sublingual (under-the-tongue) tablet for acute pain in healthcare settings, Dsuvia (sufentanil sublingual tablet, 30 mcg).


  • Medication trends shaping workers' compensation

    by
    • Optum Workers' Comp
    | Nov 01, 2018
    Tag Icon
    Workers' Compensation, Analytics
    A review of the medication trends shaping workers’ compensation, gathered from our book of business data during the first half of 2018.


  • Addressing opioid analgesic use in workers' comp and auto no-fault

    by
    • Optum for Workers' Compensation
    | Sep 11, 2018
    Tag Icon
    Auto No-Fault, Workers' Compensation, Opioids
    We are pleased to release our latest insight on addressing opioid analgesic use in workers' comp and auto no-fault. Inside you will find statistical trends impacting opioid analgesics today and our perspective on opioid analgesic use.


  • New generic version of EpiPen (epinephrine) approved

    by
    • Optum for Workers' Compensation
    | Aug 24, 2018
    Tag Icon
    Workers' Compensation, FDA
    On August 16, 2018 the U.S. Food and Drug Administration (FDA) approved Teva’s generic versions of EpiPen and EpiPen Jr (epinephrine) auto-injectors for use in adults and pediatric patients weighing more than thirty-three pounds.




Questions for our
Government Affairs team? 







Subscribe

Stay informed by signing up to receive our latest updates.